Urolithin A Benefits and Mitophagy: What Human Trials Actually Show

Urolithin A has become one of the more visible supplements in the mitochondrial health and longevity market. It is promoted for mitophagy, muscle strength, cellular energy, exercise performance, immune aging, and, increasingly, healthy longevity itself.

Unlike many compounds in this category, urolithin A is not built entirely on animal research. Randomized human trials exist. The more useful question is whether those trials support the much broader claims now attached to the ingredient.

The evidence is considerably narrower. Urolithin A appears biologically active and may influence mitochondrial pathways and selected measures of muscle function. It has not been shown to reverse aging, extend lifespan, prevent chronic disease, or reproduce the benefits of exercise.

One-Minute Read

Urolithin A is a metabolite normally produced when certain gut bacteria process ellagitannins and ellagic acid found in foods including pomegranates, walnuts, and berries. Its scientific appeal comes largely from its effect on mitophagy, one component of the mitochondrial quality-control system.

Several randomized human trials have reported encouraging findings involving muscle strength, muscle endurance, inflammatory markers, mitochondrial biomarkers, and cellular metabolism. The results are not uniform. In a 2022 trial of older adults, urolithin A improved some secondary measures of muscle endurance, while the primary outcomes involving six-minute walking distance and maximal ATP production were not significantly better than placebo. Another 2022 trial reported improvements in selected leg-strength measurements, although its primary endpoint, peak power output, did not significantly improve.

A 2026 systematic review and meta-analysis brought the evidence into better perspective. Five randomized trials involving 236 participants were identified. The pooled six-minute walk result favored urolithin A numerically but was not statistically significant, and the certainty of evidence was rated low.

For someone interested in preserving muscle and mitochondrial function with age, resistance training, adequate protein, sleep, metabolic health, and well-established interventions such as creatine still have a stronger practical foundation. Urolithin A is better viewed as a developing adjunct than a foundational longevity intervention.

What Is Urolithin A?

Urolithin A is a postbiotic metabolite produced when certain intestinal bacteria metabolize ellagitannins and ellagic acid. These compounds are present in foods including pomegranates, walnuts, raspberries, strawberries, and other plant foods.

The molecule attracted scientific attention because of its apparent effects on mitochondrial quality control, particularly mitophagy.

Mitochondria continually undergo damage, repair, recycling, fusion, division, and replacement. Mitophagy is the process through which cells identify and remove mitochondria that are damaged or no longer functioning appropriately.

Mitochondrial dysfunction becomes more common with aging, making the pathway an appealing target for longevity research. A plausible mechanism, however, is only the beginning of the clinical question. What ultimately matters is whether changing that pathway improves strength, mobility, function, disease risk, quality of life, or lifespan in humans.

Can You Get Urolithin A From Food?

Not directly in meaningful amounts. Foods such as pomegranates and walnuts provide the precursors from which gut bacteria can produce urolithin A.

Production varies considerably from one person to another because the process depends on the composition of the intestinal microbiome. Two people can eat similar amounts of ellagitannin-rich food and produce very different quantities of urolithin A.

Supplemental urolithin A bypasses this microbial conversion step by providing a standardized amount of the metabolite itself. Greater and more predictable exposure does not necessarily mean greater clinical benefit, but it does make supplementation easier to study.

How Urolithin A and Mitophagy Are Connected

The strongest biological argument for urolithin A involves its ability to stimulate pathways associated with mitophagy.

This is frequently translated in consumer advertising into phrases such as “mitochondrial renewal” or “cellular rejuvenation.” Those descriptions make a complex cellular process sound more comprehensive than it is.

Mitophagy removes dysfunctional mitochondria. Healthy mitochondrial function also depends on mitochondrial biogenesis, repair, fusion, fission, nutrient availability, metabolic health, oxygen delivery, physical activity, and appropriate recovery. Increasing one part of that system does not automatically restore the entire system.

Exercise remains the most established intervention for stimulating broad mitochondrial adaptation in human muscle. Urolithin A may influence one component of mitochondrial quality control, but it cannot reasonably be separated from physical activity, muscle loading, adequate nutrition, sleep, and metabolic health.

What Human Trials Actually Show

Early human studies established that supplemental urolithin A is absorbed and can alter molecular markers associated with mitochondrial biology. Later randomized trials began looking at physical performance and muscle function.

Middle-aged adults

A 2022 randomized, placebo-controlled trial studied 88 untrained, overweight middle-aged adults receiving placebo, 500 mg of urolithin A, or 1,000 mg daily for four months.

Selected measurements of hamstring strength improved in both urolithin A groups compared with placebo. The study also reported changes in mitochondrial biomarkers and inflammatory markers. Other outcomes were less convincing. Hand-grip strength did not significantly differ between groups, and peak power output, the primary endpoint, did not significantly improve.

The frequently advertised figure suggesting an approximately 12% improvement in muscle strength comes largely from selected hamstring measurements in this study. It should not be interpreted to mean that urolithin A makes the entire body 12% stronger.

Adults ages 65 to 90

A separate 2022 randomized trial published in JAMA Network Open evaluated 66 adults between 65 and 90 years of age who received either 1,000 mg of urolithin A daily or placebo for four months.

Muscle endurance improved on some secondary testing. Several plasma biomarkers associated with mitochondrial health also changed.

The study's two primary outcomes told a more restrained story. Improvements in six-minute walking distance and maximal ATP production in hand muscle were not significantly different from placebo.

This trial is often cited as evidence that urolithin A improves muscle function in older adults. There is a signal worth investigating, particularly for endurance. The study did not demonstrate a broad restoration of physical performance or mitochondrial energy production.

Immune aging

A randomized trial published in Nature Aging in 2025 evaluated 50 healthy middle-aged adults receiving 1,000 mg daily for four weeks. Researchers found changes in several immune-cell populations, mitochondrial biology, and measures of immune-cell metabolism and function.

These findings expand the mechanistic interest in urolithin A beyond skeletal muscle. They do not establish that supplementation prevents infections, restores the aging immune system, reduces chronic disease, or increases longevity.

What the 2026 Systematic Review Found

The most useful update came in 2026, when researchers published a systematic review and meta-analysis of randomized human trials involving urolithin A and muscle-related outcomes.

The investigators identified five randomized controlled trials involving a total of 236 participants. The trials differed enough in population, dosage, duration, and outcome measurements that most results could not be combined statistically.

The six-minute walk test was the main exception. Pooling the available data produced an estimated improvement of roughly 17 meters with urolithin A compared with placebo, but the difference did not reach statistical significance. The certainty of evidence was rated low.

Results involving strength, endurance, aerobic capacity, mitochondrial biomarkers, and biochemical measures were considered exploratory because the studies were too heterogeneous for a reliable pooled estimate.

The review therefore lands in almost exactly the position suggested by the individual trials: there are interesting biological and functional signals, but there is not yet reproducible human evidence strong enough to support firm clinical claims about muscle performance or healthy aging.

Where the Marketing Gets Ahead of the Evidence

The Funding Question

Many of the central human studies of supplemental urolithin A have been sponsored by Amazentis, the company that developed the proprietary Mitopure® ingredient. Several investigators in the published trials have also been company employees, executives, advisers, or otherwise affiliated with the sponsor.

Industry funding does not invalidate research. Nutrition, pharmaceutical, and medical-device research frequently depends on commercial support. Trial design, prespecified outcomes, statistical analysis, transparent reporting, replication, and consistency across independent research groups matter more than the source of funding alone.

The concentration of evidence around one proprietary ingredient does justify restraint when broad marketing claims are built from the same research program. Independent replication and larger trials would make the clinical case considerably stronger.

Urolithin A vs Creatine: Which Has Better Evidence?

Urolithin A and creatine are sometimes placed side by side in longevity supplement comparisons, although they address different aspects of physiology.

Creatine increases phosphocreatine availability and supports rapid regeneration of ATP during high-energy demand. Urolithin A is being investigated primarily for mitochondrial quality control and mitophagy.

Creatine has decades of human research across strength, exercise performance, aging muscle, and related outcomes. Urolithin A has a much smaller clinical literature consisting largely of short studies involving relatively small groups.

For an adult deciding where to put limited time and money, the order is difficult to ignore: resistance training, adequate protein, sleep, metabolic health, and creatine have a stronger practical evidence base for maintaining muscle and physical function.

For more on that evidence, see Creatine in Longevity Medicine and Creatine and Muscle Loss With Aging.

Urolithin A may eventually earn a clearer place alongside those interventions. Current evidence does not justify moving it ahead of them.

What Urolithin A Dosage Has Been Studied?

Human trials have commonly evaluated daily doses of 500 mg or 1,000 mg, with several mechanistic and functional studies using 1,000 mg per day.

This becomes relevant when interpreting product advertising. A finding produced with 1,000 mg of a defined study ingredient should not automatically be assigned to a product containing 500 mg, a different formulation, or an ingredient of uncertain purity and stability.

There is also no established clinical “longevity dose” of urolithin A. The research has investigated specific outcomes over relatively short periods. It has not determined an optimal dose for lifespan, prevention of age-related disease, or indefinite daily use.

Urolithin A Safety and Side Effects

Short-term human trials have generally reported that supplemental urolithin A was well tolerated at the doses studied. The available clinical literature has not identified a consistent pattern of serious treatment-related adverse effects.

That safety record should be interpreted within the duration and size of the studies. Most trials have lasted weeks to a few months and included relatively small numbers of participants.

Long-term safety, medication interactions, and use in people with significant chronic illness remain less well characterized. Pregnant or breastfeeding individuals, people undergoing cancer treatment, and those managing significant medical conditions should discuss supplementation with their treating clinician.

What Urolithin A Has Not Been Proven to Do

• Reverse biological aging
• Extend human lifespan
• Prevent cardiovascular disease, dementia, cancer, or frailty
• Produce substantial muscle growth by itself
• Cause meaningful fat loss
• Replace resistance training or adequate dietary protein
• Reliably correct fatigue or low subjective energy
• Rejuvenate the entire immune system

Biomarkers are useful when they help explain biology or predict clinically important outcomes. They are not substitutes for those outcomes. A mitochondrial protein, metabolite, inflammatory marker, or immune-cell population can change without proving that a person feels better, functions better, avoids disease, or lives longer.

Who Might Reasonably Consider Urolithin A?

Urolithin A may be reasonable to discuss for an older adult concerned about declining muscle endurance, someone interested in mitochondrial biology who has already addressed the major determinants of muscle health, or an individual who does not appear to produce substantial urolithin A from dietary precursors.

The clinical context matters more than the novelty of the supplement. Weakness, fatigue, declining performance, or loss of lean mass can reflect inadequate protein, inactivity, insulin resistance, sleep disorders, nutrient deficiencies, medication effects, hormone changes, cardiovascular disease, or other medical issues that deserve evaluation rather than another supplement.

Objective measurement can also be more useful than guessing. DEXA body composition, strength and functional testing, metabolic markers, and longitudinal changes provide a better picture of whether an intervention is accomplishing anything meaningful.

The HormoneSynergy® Perspective

Urolithin A is not an imaginary longevity compound held together by a mouse study and a marketing campaign. Its biology is credible. Randomized human trials exist. The research deserves to continue.

The clinical claims should remain proportional to the evidence.

Human trials have produced signals involving mitochondrial biology, muscle strength, endurance, inflammation, and immune-cell metabolism. The results are inconsistent across outcomes, study populations, and doses. Some prominent primary endpoints have been negative. The first systematic review of the randomized evidence found the literature too small and heterogeneous to support firm conclusions.

That places urolithin A in a fairly specific category: credible, biologically active, and still developing.

For most people interested in muscle and mitochondrial health, the less novel work still deserves priority. Resistance training provides a much broader mitochondrial stimulus. Protein provides the substrate for maintaining muscle. Creatine has a deeper human evidence base. Sleep and metabolic health influence recovery and cellular function throughout the body.

Once those pieces are in place, urolithin A may be an interesting adjunct. It should not be sold as proof that mitochondrial aging has been solved in a capsule or gummy.

Related HormoneSynergy® Resources

• Creatine in Longevity Medicine
• Creatine and Muscle Loss With Aging
• DEXA Bone Density, Body Composition and Visceral Fat Analysis
• Bioidentical Hormone and Testosterone Therapy

Selected References

• Andreux PA, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Metabolism. 2019.
• Singh A, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Reports Medicine. 2022.
• Liu S, et al. Effect of urolithin A supplementation on muscle endurance and mitochondrial health in older adults. JAMA Network Open. 2022.
• Denk D, et al. Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial. Nature Aging. 2025.
• Dao T, et al. Effects of Urolithin A supplementation on muscle health outcomes in humans from randomized controlled trials. Frontiers in Nutrition. 2026.

Frequently Asked Questions

What are the benefits of urolithin A?

Human trials suggest that urolithin A can influence mitophagy-related pathways, mitochondrial biomarkers, and selected measures of muscle strength or endurance. The evidence is not yet consistent enough to conclude that it broadly improves physical function, energy, or healthy aging.

Does urolithin A really work?

Urolithin A is biologically active, but “works” depends on the outcome being measured. Some randomized trials have reported favorable changes in selected muscle and mitochondrial measures, while several important primary outcomes have not been significantly better than placebo. A 2026 systematic review concluded that current human evidence remains limited and low-certainty.

Does urolithin A reverse aging?

No. Urolithin A may influence mitophagy and other cellular pathways associated with aging, but no human trial has shown that it reverses biological aging or extends lifespan.

Can urolithin A replace exercise?

No. Urolithin A has not been shown to reproduce the broad muscular, mitochondrial, metabolic, cardiovascular, skeletal, and neurologic adaptations produced by regular exercise.

What dose of urolithin A has been studied?

Human trials have commonly studied 500 mg or 1,000 mg daily. Several frequently cited mechanistic findings used 1,000 mg per day. There is no established dose proven to extend lifespan or prevent age-related disease.

What are the side effects of urolithin A?

Short-term studies have generally found urolithin A to be well tolerated. Long-term safety, medication interactions, and use in people with significant chronic illness remain less well established.

Is urolithin A better than creatine?

They work through different mechanisms and have not been adequately compared head-to-head. Creatine has a substantially larger independent human evidence base for strength and exercise-related outcomes. For most adults focused on preserving muscle with age, creatine, resistance training, and adequate protein have a stronger practical foundation.

Is Mitopure® the same as urolithin A?

Mitopure® is a proprietary standardized form of urolithin A developed by Amazentis. Much of the published human research has involved this ingredient. Results from those studies should not automatically be applied to products with different doses, purity, identity, or stability.

Can you get urolithin A naturally from food?

Foods such as pomegranates, walnuts, and some berries contain ellagitannins and ellagic acid that certain gut bacteria can convert into urolithin A. The amount produced varies considerably among individuals because of differences in the gut microbiome.

Editorial Transparency: HormoneSynergy® has no financial relationship with Timeline or Amazentis and did not receive compensation for this article. This review distinguishes mechanistic findings, biomarkers, functional outcomes, and unproven longevity claims. It is educational and is not a substitute for individualized medical care.